GMP Certified / Esomeprazole Sodium for Injection 40mg

• Customization: Available
• Quality Standard: USP, Bp
• Packing: 1 Vial+1 AMP/Box
• Model NO.: injection
• Factory Certified: GMP
• Ctd Document: Available
• Transport Package: Carton
• Specification: 40mg
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

Generic Name	Esomeprazole Sodium for injection 40mg
Strength	40mg
Packing	1 vial+1 amp / box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Esomeprazole Sodium for injection

Character:
 This product is white or white like lump or powder.

Indications:
1. As an alternative treatment for gastroesophageal reflux disease when oral therapy is not available.
2. For low-risk patients with acute gastric or duodenal ulcer bleeding for which oral therapy is not applicable (gastroscopy
Forrest Classification IIc-III).

Taboo:
Known allergy to esomeprazole, other benzimidazole compounds or any other component of this product
Is prohibited.
This product is not allowed to be used in combination with nelfinavir; Not recommended with Azanavir
(atazanavir) in combination with saquinavir (see Drug Interactions).

Pharmacology and toxicology
Pharmacological action
It is a specific inhibitor of proton pump in gastric parietal cells. Esomeprazole is the S- of omeprazole
The R isomer of omeprazole and the S isomer have similar pharmacodynamic properties by reducing gastric acid secretion through specific proton pump inhibition.
Esomeprazole is a weakly alkaline drug that is concentrated and transformed into a high-acid environment in which parietal cells secrete acid microtubules
The active form, thereby inhibiting the H of the site
+
/K+ -ATPase (proton pump), which secretes and stimulates basic gastric acid
The secretion of gastric acid was inhibited.
Patients with gastroesophageal reflux disease (GERD) who took esomeprazole 20mg and 40mg orally daily had 24 less after 5 days
Intragastric pH&gt was maintained; The average time of 4 was 13 hours and 17 hours, respectively. Esomeprazole orally or intravenously
The effect of drug administration is similar.
The AUC(area under the blood concentration-time curve) can also be used to show inhibition of gastric acid secretion after oral administration
The relationship between drug exposure.
Healthy subjects received 80mg esomeprazole (30 min intravenously) followed by continuous rest
After a pulse infusion of 23.5 hours (8mg/h), within 24 hours, intragastric pH> 4, and pH> The average duration of 6 respectively
For 21 hours and 11 to 13 hours.
In patients with reflux esophagitis who took esomeprazole 40mg orally for 4 weeks, the healing rate was about 78% and 93% after 8 weeks.
Enterochromaffin has been observed in some children and adults treated with esomeprazole over a long period of time
(ECL) cells increase, which may be related to elevated serum gastrin levels. These findings are thought not to have
Clinical significance.
A certain increase in the incidence of gastric gland cysts has been reported during long-term antacid therapy. this
Some reactions significantly inhibit the physiological reaction after acid secretion, which is benign and reversible.
Reducing the acidity of gastric juices by any means, including proton pump inhibitors, can increase the bacteria in the stomach
Quantity (usually present in the gastrointestinal tract). Treatment with proton pump inhibitors can lead to gastrointestinal infections (such as salmonella)
Bacteria and campylobacter) had a slightly increased risk. And in hospitalized patients, it may also cause clostridium difficile
There is a slightly increased risk of gastrointestinal infections.
Toxicity study
A carcinogenicity study of oral racemic mixture (omeprazole) in rats found intestinal chromaffin-like (ECL) fineness of the stomach
Cell hyperplasia and carcinoid. These effects are secondary to a sustained reduction in gastric acid production and significant hypergastrinemia, see
In rats after long-term administration of gastric acid secretion inhibitors. Non-clinical analysis on esomeprazole intravenous dosage forms
In the bed study, there was no evidence of vascular stimulation after subcutaneous (paravenous) injection, but it was noted
Slight tissue inflammation at the injection site.

Storage:
Keep out of light and tightly sealed.